Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia

Phase 2

Completed

Conditions: Anemia
Myelodysplastic/Myeloproliferative Neoplasm
Myelofibrosis

Interventions: Biological: Sotatercept
Drug: Ruxolitinib

First Posted Date: 2012-10-23

Last Posted Date: 2023-10-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 56

Registration Number: NCT01712308

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

Phase 2

Active, not recruiting

Conditions: Thyroid Cancer

Interventions: Drug: Vemurafenib (All Groups)
Drug: Vemurafenib (Post Surgery) - Group A + C
Other: Post Surgery - Group B

First Posted Date: 2012-10-18

Last Posted Date: 2025-05-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT01709292

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Magnetic Resonance Imaging (MRI) Brachytherapy Applicator Study

Not Applicable

Completed

Conditions: Cervical Cancer

Interventions: Device: Intracavitary Applicator Placement
Other: Computed Tomography (CT)
Other: Magnetic Resonance Imaging (MRI)

First Posted Date: 2012-10-15

Last Posted Date: 2022-02-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 57

Registration Number: NCT01706705

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Magnetic Resonance Imaging of Gynecologic Malignancies Involving the Vagina

Not Applicable

Completed

Conditions: Vaginal Cancer

Interventions: Procedure: Magnetic Resonance Imaging (MRI)
Procedure: Diffusion Weighted Magnetic Resonance Imaging (DWMR)

First Posted Date: 2012-10-10

Last Posted Date: 2019-09-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 12

Registration Number: NCT01703195

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Phase 1

Completed

Conditions: Refractory Hodgkin Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Refractory T-Cell Non-Hodgkin Lymphoma
Hematopoietic Cell Transplantation Recipient

Interventions: Procedure: Allogeneic Bone Marrow Transplantation
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Biological: Anti-Thymocyte Globulin
Drug: Busulfan
Drug: Clofarabine
Drug: Gemcitabine Hydrochloride
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Pharmacological Study
Biological: Rituximab
Drug: Tacrolimus

First Posted Date: 2012-10-05

Last Posted Date: 2025-02-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 64

Registration Number: NCT01701986

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

IADAPT-Third Phase

Completed

Conditions: Musculoskeletal Diseases

Interventions: Other: Multimedia Patient Decision Aids (MM-PtDAs)
Other: Comparative Effectiveness Research Summary Guide (CERSG)
Behavioral: Questionnaires

First Posted Date: 2012-10-03

Last Posted Date: 2021-05-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 676

Registration Number: NCT01698762

Locations: 🇺🇸
Kelsey-Seybold Clinic, Houston, Texas, United States
🇺🇸
Harris County Hospital District (HCHD), Houston, Texas, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

An Endometrial Cancer Chemoprevention Study of Metformin

Phase 3

Completed

Conditions: Gynecology

Interventions: Other: Placebo
Drug: Metformin
Procedure: Endometrial Biopsy
Behavioral: Lifestyle Intervention
Behavioral: Questionnaires

First Posted Date: 2012-10-02

Last Posted Date: 2025-06-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 29

Registration Number: NCT01697566

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Domperidone in Treating Patients with Gastrointestinal Disorders

Phase 3

Recruiting

Conditions: Dyspepsia
Gastroesophageal Reflux Disease
Gastroparesis
Heartburn
Nausea and Vomiting
Esophagitis
Digestive System Disorder

Interventions: Drug: Domperidone
Other: Questionnaire Administration

First Posted Date: 2012-10-01

Last Posted Date: 2025-02-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 200

Registration Number: NCT01696734

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Minocycline Study in Pancreatic Cancer Patients

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Other: Placebo
Drug: Minocycline
Behavioral: Questionnaires

First Posted Date: 2012-09-26

Last Posted Date: 2020-03-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT01693523

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

The Effect of Dexmedetomidine of the Immune System

Completed

Conditions: Breast Cancer

Interventions: Drug: Dexmedetomidine

First Posted Date: 2012-09-25

Last Posted Date: 2016-01-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT01692210

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy